Retigabine (D-23129) 作为一种新型抗惊厥药物，在多种癫痫模型中表现出广谱活性，其作用机制主要通过激活神经元KCNQ2-5电压门控钾离子通道实现。
|
英文别名 (English Synonym) |
Retigabine |
|
中文名称 (Chinese Name) |
瑞替加滨 |
|
靶点 (Target) |
Potassium Channel |
|
通路 (Pathway) |
Membrane Transporter/Ion Channel |
|
CAS号 (CAS NO.) |
150812-12-7 |
|
分子式 (Formula) |
C16H18FN3O2 |
|
分子量 (Molecular Weight) |
303.33 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. PMID: 22220513. [2] Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 2005 Spring;11(1):1-20. doi: 10.1111/j.1527-3458.2005.tb00033.x. PMID: 15867950; PMCID: PMC6741764.
